560 related articles for article (PubMed ID: 26320061)
1. Enhancing Cancer Immunotherapy Via Activation of Innate Immunity.
Goldberg JL; Sondel PM
Semin Oncol; 2015 Aug; 42(4):562-72. PubMed ID: 26320061
[TBL] [Abstract][Full Text] [Related]
2. Roles for Innate Immunity in Combination Immunotherapies.
Moynihan KD; Irvine DJ
Cancer Res; 2017 Oct; 77(19):5215-5221. PubMed ID: 28928130
[TBL] [Abstract][Full Text] [Related]
3. Innate immune mediators in cancer: between defense and resistance.
Berraondo P; Minute L; Ajona D; Corrales L; Melero I; Pio R
Immunol Rev; 2016 Nov; 274(1):290-306. PubMed ID: 27782320
[TBL] [Abstract][Full Text] [Related]
4. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation.
Ferris RL; Lenz HJ; Trotta AM; García-Foncillas J; Schulten J; Audhuy F; Merlano M; Milano G
Cancer Treat Rev; 2018 Feb; 63():48-60. PubMed ID: 29223828
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines.
Butt AQ; Mills KH
Oncogene; 2014 Sep; 33(38):4623-31. PubMed ID: 24141774
[TBL] [Abstract][Full Text] [Related]
6. Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists.
Beatty GL; Li Y; Long KB
Expert Rev Anticancer Ther; 2017 Feb; 17(2):175-186. PubMed ID: 27927088
[TBL] [Abstract][Full Text] [Related]
7. Targeting innate immune pathways in cancer immunotherapy: state of the art.
Mastellos DC
J BUON; 2009 Sep; 14 Suppl 1():S123-30. PubMed ID: 19785054
[TBL] [Abstract][Full Text] [Related]
8. Manipulation of Innate and Adaptive Immunity through Cancer Vaccines.
Sayour EJ; Mitchell DA
J Immunol Res; 2017; 2017():3145742. PubMed ID: 28265580
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.
Aguilar LK; Guzik BW; Aguilar-Cordova E
J Cell Biochem; 2011 Aug; 112(8):1969-77. PubMed ID: 21465529
[TBL] [Abstract][Full Text] [Related]
10. New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors.
Ciccarese C; Alfieri S; Santoni M; Santini D; Brunelli M; Bergamini C; Licitra L; Montironi R; Tortora G; Massari F
Expert Opin Drug Metab Toxicol; 2016; 12(1):57-75. PubMed ID: 26565919
[TBL] [Abstract][Full Text] [Related]
11. Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy.
Ginefra P; Lorusso G; Vannini N
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32580431
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for pancreatic cancer: present and future.
Aroldi F; Zaniboni A
Immunotherapy; 2017 Jun; 9(7):607-616. PubMed ID: 28595517
[TBL] [Abstract][Full Text] [Related]
13. Use of adjuvants for immunotherapy.
Circelli L; Tornesello M; Buonaguro FM; Buonaguro L
Hum Vaccin Immunother; 2017 Aug; 13(8):1774-1777. PubMed ID: 28604160
[TBL] [Abstract][Full Text] [Related]
14. Nucleic Acid Sensing Machinery: Targeting Innate Immune System for Cancer Therapy.
Iurescia S; Fioretti D; Rinaldi M
Recent Pat Anticancer Drug Discov; 2018; 13(1):2-17. PubMed ID: 29086701
[TBL] [Abstract][Full Text] [Related]
15. Cancer Immunotherapy: Priming the Host Immune Response with Live Attenuated
Hernández-Luna MA; Luria-Pérez R
J Immunol Res; 2018; 2018():2984247. PubMed ID: 30302344
[TBL] [Abstract][Full Text] [Related]
16. Principles of immunotherapy.
Olszanski AJ
J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):670-2. PubMed ID: 25995426
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint modulation: rational design of combination strategies.
Zamarin D; Postow MA
Pharmacol Ther; 2015 Jun; 150():23-32. PubMed ID: 25583297
[TBL] [Abstract][Full Text] [Related]
18. Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors.
Chester C; Marabelle A; Houot R; Kohrt HE
Curr Opin Immunol; 2015 Apr; 33():1-8. PubMed ID: 25576932
[TBL] [Abstract][Full Text] [Related]
19. Multi-Immune Agonist Nanoparticle Therapy Stimulates Type I Interferons to Activate Antigen-Presenting Cells and Induce Antigen-Specific Antitumor Immunity.
Levy ES; Chang R; Zamecnik CR; Dhariwala MO; Fong L; Desai TA
Mol Pharm; 2021 Mar; 18(3):1014-1025. PubMed ID: 33541072
[TBL] [Abstract][Full Text] [Related]
20. Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines.
Schijns V; Tartour E; Michalek J; Stathopoulos A; Dobrovolskienė NT; Strioga MM
Cytotherapy; 2014 Apr; 16(4):427-39. PubMed ID: 24280238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
